Concert Pharmaceuticals Company Profile (NASDAQ:CNCE)

About Concert Pharmaceuticals

Concert Pharmaceuticals logoConcert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386. The Company's deuterated chemical entity platform (DCE Platform) enables it to identify compounds for deuteration and to design, evaluate, develop and manufacture deuterated compounds. The Company is utilizing its DCE Platform to discover and develop product candidates for a range of indications. The Company's product candidate, CTP-656, is a next generation potentiator that the Company is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. AVP-786 is a combination of a deuterated dextromethorphan analog and a low dose of quinidine.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CNCE
  • CUSIP:
Key Metrics:
  • Previous Close: $9.73
  • 50 Day Moving Average: $10.33
  • 200 Day Moving Average: $11.96
  • 52-Week Range: $9.47 - $25.04
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.21
  • P/E Growth: 0.00
  • Market Cap: $216.27M
  • Outstanding Shares: 22,227,000
  • Beta: 1.46
Profitability:
  • Net Margins: -289.85%
  • Return on Equity: -29.09%
  • Return on Assets: -25.64%
Debt:
  • Current Ratio: 17.15%
  • Quick Ratio: 17.15%
Additional Links:
Companies Related to Concert Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Concert Pharmaceuticals (NASDAQ:CNCE) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.50 (172.35% upside)

Analysts' Ratings History for Concert Pharmaceuticals (NASDAQ:CNCE)
Show:
DateFirmActionRatingPrice TargetDetails
9/27/2016Stifel NicolausReiterated RatingBuy$23.00View Rating Details
9/7/2016Brean CapitalReiterated RatingBuy$25.00View Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$28.00 -> $24.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$28.00 -> $24.00View Rating Details
1/26/2016AegisReiterated RatingBuyView Rating Details
10/8/2015Roth CapitalInitiated CoverageBuy$32.00View Rating Details
6/24/2015Ladenburg ThalmannBoost Price TargetBuy$24.00 -> $27.00View Rating Details
(Data available from 9/30/2014 forward)

Earnings

Earnings History for Concert Pharmaceuticals (NASDAQ:CNCE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/9/2016Q2($0.63)($0.60)ViewN/AView Earnings Details
5/5/2016Q116($0.45)($0.63)$1.24 millionViewN/AView Earnings Details
3/1/2016Q415($0.05)$0.03$11.24 million$10.30 millionViewN/AView Earnings Details
11/5/2015Q315($0.41)($0.39)$4.50 million$1.70 millionViewListenView Earnings Details
8/5/2015Q215($0.46)$1.80$1.66 million$3.25 millionViewListenView Earnings Details
5/8/2015Q115($0.38)($0.48)$2.70 million$1.30 millionViewListenView Earnings Details
2/27/2015Q414($0.60)($0.48)$1.38 millionViewN/AView Earnings Details
11/12/2014Q314($0.49)($0.43)$1.67 million$4.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.42)($0.45)$1.30 million$1.20 millionViewN/AView Earnings Details
5/14/2014Q114($0.49)($0.76)$0.44 million$1.61 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Concert Pharmaceuticals (NASDAQ:CNCE)
Current Year EPS Consensus Estimate: $-2.5 EPS
Next Year EPS Consensus Estimate: $-2.31 EPS

Dividends

Dividend History for Concert Pharmaceuticals (NASDAQ:CNCE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Concert Pharmaceuticals (NASDAQ:CNCE)
Insider Ownership Percentage: 15.30%
Institutional Ownership Percentage: 61.68%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2016Thomas G AuchinclossDirectorBuy2,000$10.11$20,220.00View SEC Filing  
5/11/2016Roger D TungCEOBuy19,610$10.55$206,885.50View SEC Filing  
12/16/2015Wilfred E JaegerDirectorSell10,360$19.57$202,745.20View SEC Filing  
12/15/2015Wilfred E JaegerDirectorSell54,572$20.10$1,096,897.20View SEC Filing  
12/14/2015Pauline McgowanVPSell498$20.07$9,994.86View SEC Filing  
12/14/2015Wilfred E JaegerDirectorSell3,922$20.09$78,792.98View SEC Filing  
11/9/2015Ronald W. BarrettDirectorSell17,699$22.27$394,156.73View SEC Filing  
11/2/2015Nancy StuartCOOSell23,216$24.29$563,916.64View SEC Filing  
9/18/2015Robert SilvermanVPSell10,000$20.00$200,000.00View SEC Filing  
9/10/2015Wilfred E JaegerDirectorSell120,000$18.22$2,186,400.00View SEC Filing  
8/18/2015Wilfred E JaegerDirectorSell760,000$15.81$12,015,600.00View SEC Filing  
8/13/2015Wilfred E JaegerDirectorSell92,215$16.75$1,544,601.25View SEC Filing  
8/12/2015Wilfred E JaegerDirectorSell97,785$17.49$1,710,259.65View SEC Filing  
6/8/2015Robert SilvermanVPSell5,000$16.35$81,750.00View SEC Filing  
3/11/2015Nancy StuartCOOSell46,430$15.00$696,450.00View SEC Filing  
3/11/2015Pauline McgowanVPSell5,973$16.00$95,568.00View SEC Filing  
3/10/2015Pauline McgowanVPSell22,122$13.90$307,495.80View SEC Filing  
11/18/2014Three Arch Management Iv, L.L.DirectorSell250,000$12.29$3,072,500.00View SEC Filing  
2/20/2014Skyline Venture Partners QualiMajor ShareholderBuy150,000$14.00$2,100,000.00View SEC Filing  
2/19/2014Life Science Ventures Vi G TvmDirectorBuy89,000$14.00$1,246,000.00View SEC Filing  
2/19/2014Plc GlaxosmithklineMajor ShareholderBuy35,000$14.00$490,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Concert Pharmaceuticals (NASDAQ:CNCE)
DateHeadline
News IconConcert Pharmaceuticals Inc (CNCE) Updated Broker Price Targets - The De Soto Edge (NASDAQ:CNCE)
desotoedge.com - September 29 at 4:12 PM
investornewswire.com logoConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Mean Price Target At $27.8. - Investor Newswire (NASDAQ:CNCE)
www.investornewswire.com - September 28 at 4:11 PM
News IconAnalyst Review: Concert Pharmaceuticals Inc (CNCE) - NewsDen (NASDAQ:CNCE)
newsden.net - September 28 at 9:10 AM
businesswire.com logoConcert Pharmaceuticals Announces Upcoming Poster Presentation at North American Cystic Fibrosis Conference - Business Wire (press release) (NASDAQ:CNCE)
www.businesswire.com - September 23 at 3:42 PM
News IconWill Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) beat earning ... - The Independent Republic (NASDAQ:CNCE)
theindependentrepublic.com - September 23 at 3:42 PM
finance.yahoo.com logoConcert Pharmaceuticals Announces Upcoming Poster Presentation at North American Cystic Fibrosis Conference (NASDAQ:CNCE)
finance.yahoo.com - September 21 at 4:55 PM
News IconStock Tracker: Earnings & Estimates for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Frisco Fastball (NASDAQ:CNCE)
friscofastball.com - September 21 at 8:21 AM
News IconParrent Watching: A Reversal for Concert Pharmaceuticals Inc Is Not Near. The Formed Bearish Double Bottom Pattern - Chester News (NASDAQ:CNCE)
www.chesterindependent.com - September 19 at 5:04 PM
News IconConcert Pharmaceuticals Incorporated (NASDAQ:CNCE) Shorts Decreased by 15.99% After Short Covering - Post News (NASDAQ:CNCE)
www.kentuckypostnews.com - September 17 at 9:03 AM
News IconAnalysts Take Aim At This Stock's Earnings Estimates: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Frisco Fastball (NASDAQ:CNCE)
friscofastball.com - September 16 at 5:30 AM
bloomberg.com logoA Decades-Old Drug Technology Finally Nears Its Big Breakthrough (NASDAQ:CNCE)
www.bloomberg.com - September 16 at 5:30 AM
News IconSell-side Consensus Sees Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Going Where Near-Term? - Frisco Fastball (NASDAQ:CNCE)
friscofastball.com - September 9 at 9:06 AM
News IconPlacing Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Shares Under the Microscope - Post News (NASDAQ:CNCE)
www.kentuckypostnews.com - September 8 at 8:00 AM
News IconBrean Capital Reiterates Buy at Concert Pharmaceuticals Inc. (NASDAQ: CNCE) - BNB Daily (blog) (NASDAQ:CNCE)
www.baseball-news-blog.com - September 8 at 8:00 AM
businesswire.com logoConcert Pharmaceuticals Expands Management Team - Business Wire (press release) (NASDAQ:CNCE)
www.businesswire.com - September 7 at 7:53 AM
finance.yahoo.com logoConcert Pharmaceuticals Expands Management Team (NASDAQ:CNCE)
finance.yahoo.com - September 6 at 9:10 AM
biz.yahoo.com logoCONCERT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:CNCE)
biz.yahoo.com - September 6 at 9:10 AM
finance.yahoo.com logoConcert Pharmaceuticals to Present at Upcoming Investor Conferences - Yahoo Finance (NASDAQ:CNCE)
finance.yahoo.com - September 1 at 11:17 AM
publicnow.com logoConcert Pharmaceuticals to Present at Upcoming Investor Conferences (NASDAQ:CNCE)
www.publicnow.com - September 1 at 11:17 AM
capitalcube.com logoETF’s with exposure to Concert Pharmaceuticals, Inc. : August 29, 2016 (NASDAQ:CNCE)
www.capitalcube.com - August 29 at 4:30 PM
live-pr.com logoConcert Pharmaceuticals, Inc. (CNCE) - Financial and Strategic SWOT Analysis Review - New Report Available (NASDAQ:CNCE)
www.live-pr.com - August 26 at 4:15 PM
investornewswire.com logoWill Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Surprise This Quarter? - Investor Newswire (NASDAQ:CNCE)
www.investornewswire.com - August 25 at 4:21 PM
finance.yahoo.com logoCONCERT PHARMACEUTICALS, INC. Financials (NASDAQ:CNCE)
finance.yahoo.com - August 18 at 4:19 PM
capitalcube.com logoConcert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:CNCE)
www.capitalcube.com - August 11 at 4:25 PM
News IconConcert Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Company Update (NASDAQ:CNCE)
www.digitaljournal.com - August 9 at 11:14 AM
sg.finance.yahoo.com logoConcert reports 2Q loss (NASDAQ:CNCE)
sg.finance.yahoo.com - August 9 at 11:14 AM
biz.yahoo.com logoCONCERT PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:CNCE)
biz.yahoo.com - August 9 at 11:14 AM
benzinga.com logoConcert Pharmaceuticals to Report Second Quarter... (NASDAQ:CNCE)
www.benzinga.com - August 2 at 9:05 AM
publicnow.com logoConcert Pharmaceuticals to Report Second Quarter 2016 Financial Results on August 9, 2016 (NASDAQ:CNCE)
www.publicnow.com - August 2 at 9:05 AM
News IconConcert Pharmaceuticals, Inc. (NASDAQ:CNCE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:CNCE)
www.engelwooddaily.com - July 22 at 11:35 AM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - TGP (NASDAQ:CNCE)
telanaganapress.com - July 20 at 11:39 PM
News IconHeightened Volatility Spotted on Shares of: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Engelwood Daily (NASDAQ:CNCE)
www.engelwooddaily.com - July 20 at 11:39 PM
News IconBvf INC Increased Concert Pharmaceuticals INC (NASDAQ:CNCE) by $6.80 Million as Shares Declined - Consumer Eagle (NASDAQ:CNCE)
www.consumereagle.com - July 17 at 8:55 AM
News IconShares Moving Down on the Week: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Engelwood Daily (NASDAQ:CNCE)
www.engelwooddaily.com - July 17 at 8:55 AM
News IconHow Analysts Rated Concert Pharmaceuticals Inc (NASDAQ:CNCE) Last Week? - Consumer Eagle (NASDAQ:CNCE)
www.consumereagle.com - July 16 at 4:14 PM
News IconShares Experiencing a Downtrend: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - TGP (NASDAQ:CNCE)
telanaganapress.com - July 16 at 6:58 AM
News IconConcert Pharmaceuticals Inc's Stock Is Sell After Today's Huge Decline - Press Telegraph (NASDAQ:CNCE)
presstelegraph.com - July 15 at 10:59 AM
ftsenews.co.uk logoNew Broker Ratings For Concert Pharmaceuticals Inc (CNCE) - FTSE News (NASDAQ:CNCE)
www.ftsenews.co.uk - July 15 at 10:59 AM
News IconConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:CNCE)
www.engelwooddaily.com - July 15 at 10:59 AM
News IconConcert Pharmaceuticals Incorporated (NASDAQ:CNCE) Shorted Shares Decreased By 11.37% - Press Telegraph (NASDAQ:CNCE)
presstelegraph.com - July 14 at 9:50 PM
News IconInsiders Increasing Positions in: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Press Telegraph (NASDAQ:CNCE)
presstelegraph.com - July 13 at 9:40 PM
News IconConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:CNCE)
telanaganapress.com - July 13 at 12:23 PM
News IconCONCERT PHARMACEUTICALS (NASDAQ:CNCE) Institutional Investors Sentiment - Consumer Eagle (NASDAQ:CNCE)
www.consumereagle.com - July 13 at 12:23 PM
fiscalstandard.com logoBroker Outlook For Concert Pharmaceuticals Inc (CNCE) - Fiscal Standard (NASDAQ:CNCE)
www.fiscalstandard.com - July 13 at 12:23 PM
investornewswire.com logoWill Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Surprise Analysts? - Investor Newswire (NASDAQ:CNCE)
www.investornewswire.com - July 12 at 8:33 AM
News IconConcert Pharmaceuticals Incorporated (NASDAQ:CNCE) Shorts Decreased by 11.37% After Short Covering - Engelwood Daily (NASDAQ:CNCE)
www.engelwooddaily.com - July 10 at 8:54 AM
fiscalstandard.com logoConcert Pharmaceuticals Inc (CNCE) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:CNCE)
www.fiscalstandard.com - July 10 at 8:54 AM
News IconBvf INC Increased Concert Pharmaceuticals INC (NASDAQ:CNCE) by $6.80 Million as Shares Declined - Press Telegraph (NASDAQ:CNCE)
presstelegraph.com - July 9 at 6:46 AM
News IconCompany Stock Focus for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Which Way Will Shares Head? - Press Telegraph (NASDAQ:CNCE)
presstelegraph.com - July 8 at 11:58 AM
finance.yahoo.com logoConcert Pharmaceuticals Announces Webcast at Cantor Fitzgerald Healthcare Conference - Yahoo Finance (NASDAQ:CNCE)
finance.yahoo.com - July 7 at 4:18 PM

Social

Concert Pharmaceuticals (NASDAQ:CNCE) Chart for Friday, September, 30, 2016


Last Updated on 9/30/2016 by MarketBeat.com Staff